PFDN5 Antikörper

Produktnummer ABIN1682853

Der Kaninchen Monoklonal anti-PFDN5 Antikörper (ABIN1682853) detektiert spezifisch PFDN5 in WB und IF. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für PFDN5 Antikörper (ABIN1682853)

Target: PFDN5 (Prefoldin Subunit 5 (PFDN5))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser PFDN5 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (IF)

Produktdetails anti-PFDN5 Antikörper

Kreuzreaktivität: Human, Maus, Ratte

Produktmerkmale: Monoclonal Antibodies

Aufreinigung: Affinity purification

Immunogen: A synthesized peptide derived from human PFDN5

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB,1:500 - 1:2000,IF,1:50 - 1:200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS with 0.02 % sodium azide,0.05 % BSA,50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Avoid freeze / thaw cycles.

Details zu PFDN5

Target: PFDN5 (Prefoldin Subunit 5 (PFDN5))

Andere Bezeichnung: PFDN5

Hintergrund: This gene encodes a member of the prefoldin alpha subunit family. The encoded protein is one of six subunits of prefoldin, a molecular chaperone complex that binds and stabilizes newly synthesized polypeptides, thereby allowing them to fold correctly. The complex, consisting of two alpha and four beta subunits, forms a double beta barrel assembly with six protruding coiled-coils. The encoded protein may also repress the transcriptional activity of the proto-oncogene c-Myc. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008],MM-1, MM1, PFD5,Epigenetics & Nuclear Signaling,Signal Transduction,PFDN5

Molekulargewicht: 17 kDa

Gen-ID: 5204

UniProt: Q99471

Pathways: Unfolded Protein Response